Media

Glivec® (imatinib)

Glivec® (imatinib), which is known as "Gleevec" in the United States, is a cancer treatment indicated for:

• Adult and pediatric patients with newly diagnosed Ph+ Chronic Myeloid Leukemia for whom bone marrow transplantation is not considered as the first line of treatment.
• Adult and pediatric patients with Ph+ Chronic Myeloid Leukemia in chronic phase after failure of interferon-alfa therapy, or in accelerated phase or blast crisis.
• Adult patients with newly diagnosed Ph+ ALL integrated with chemotherapy.
• Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
• Adult patients with Myelodysplastic Syndrome/Myeloproliferative Diseases (MDS/MPD) associated with Platelet-Derived Growth Factor Receptor (PDGFR) gene rearrangements.
• Adult patients with advanced Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) with FIP1L1-PDGFRa rearrangement.

Glivec is also indicated for:

• Adult patients with Kit (CD117)-positive unresectable and/or metastatic malignant Gastrointestinal Stromal Tumours (GIST)
• Adult patients with unresectable Dermatofibrosarcoma Protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.